Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC017 phase Ib/IIa dose-escalation and proof-of-concept study in treatment-naive adults with HIV-1 infection
CTR20243051Phase 2Completed
- Sponsor
- Aidi Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asuptegravir in Human immunodeficiency virus infection type 1, sponsored by Aidi Pharma. Started Aug 2024; status: completed.
02
Drugs
asuptegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20243051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243051.